More on Valproate-Induced Hyperammonemia Reports of Fatal Status Epilepticus and Tardive Dyskinesia with Olanzapine Hypersensitivity Syndrome Associated with Efavirenz Therapy Acute Hepatitis after Ingestion of Herbs ADRs with Various Antidepressants
Restricted accessOtherFirst published online April, 2000
More on Valproate-Induced Hyperammonemia Reports of Fatal Status Epilepticus and Tardive Dyskinesia with Olanzapine Hypersensitivity Syndrome Associated with Efavirenz Therapy Acute Hepatitis after Ingestion of Herbs ADRs with Various Antidepressants
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (1-800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
ShusterJ.ISMP adverse drug reaction reports: Valproate and hyperammonemia. Hosp Pharm.1999; 34: 1389–90.
2.
EadieM.J., HooperW.D., DickinsonR.G.Valproate-associated hepatotoxicity and its biochemical mechanisms. Med Toxicol.1988; 3: 85–106.
3.
PannikkarG.P., GilmanS.M.Valproate-induced hyperammonemia in the psychiatric setting: Two cases. J Clin Psych.1999: 60; 557–9.
4.
WyderskiR.J., StarrettW.G., Abou-SaifA.Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother.1999; 33: 787–9.
